EIQ
Director Trades
| Date | Director | Value |
|---|---|---|
| Mr Stephen Picton | $227,757 |
Company News
Echo IQ Reports Strong US Performance of EchoSolv AS Platform Ahead of Regulatory Clearance
Perth-based medical technology company Echo IQ (ASX: EIQ) has reported strong operational momentum from its EchoSolv AS platform in the US market, with a 153% increase in echocardiograms over the three months to September. The performance has come about through extensive engagement with US hospital groups, which have integrated the technology into their operations, resulting in the […]
Echo IQ Secures Echosolv Reseller Agreement with SARC MedIQ to Broaden US Uptake
Echo IQ (ASX: EIQ) will expand the use of its EchoSolv AI software through a US network of hospitals and cardiology practices after locking in a reseller agreement with provider SARC MedIQ. Under the terms, EchoSolv will be utilised by more than 1,500 physicians at over 300 healthcare facilities and clinics within SARC’s network in […]
Echo IQ signs partnership agreement with ScImage to distribute EchoSolv AI cardiac software
Medical technology company Echo IQ (ASX: EIQ) has secured a partnership agreement with US-based ScImage Inc that will make its EchoSolv artificial intelligence (AI) medical software available to medical practitioners within the next three months. The system aims to provide medical practitioners with access to high-quality, automated and AI-backed echocardiography assessments to assist in the […]
Echo IQ trial shows EchoSolv screening platform improves diagnosis of severe aortic stenosis
A flagship clinical trial of Echo IQ’s (ASX: EIQ) EchoSolv artificial intelligence (AI) medical software technology has identified 72% more patients with severe aortic stenosis than human diagnosis alone. The trial was designed to test the effectiveness of the screening platform in identifying patients at risk of dying from the condition, which is reported to […]
Echo IQ closer to commercialising EchoSolv heart screening platform
Medical technology company Echo IQ (ASX: EIQ) has reported the achievement of several milestones during the six months to December as it advances towards commercialisation of its EchoSolv heart disease screening platform. The company increased its profile with leading influencers in the scientific and healthcare communities, demonstrated positive results in two clinical trials and positioned […]
EchoSolv commercialisation and clinical studies dominate quarter for Echo IQ
Artificial intelligence and medical technology company Echo IQ (ASX: EIQ) has cited US commercialisation plans and ongoing clinical studies for its EchoSolv heart disease screening platform as its main areas of focus for the three months to December 2022. The company moved closer to the commercial introduction of its cloud-based solution for the retrospective and […]
Echo IQ reports positive results from EchoSolv trial to identify severe aortic stenosis
Medical technology company Echo IQ (ASX: EIQ) has released positive interim results from a clinical trial demonstrating the artificial intelligence of its EchoSolv technology for the identification of severe aortic stenosis (AS). The trial was conducted at St Vincent’s Hospital in Melbourne with the aim of evaluating whether the innovative decision-making platform could enhance the […]
Echo IQ launches EchoSolv heart disease screening platform to US market
Sydney-based medical technology company Echo IQ (ASX: EIQ) has confirmed its flagship structural heart disease screening platform EchoSolv is now available to registered customers in the US. The cloud-based enhanced product has been developed and rigorously tested in consultation with leading cardiologists. It is designed to support clinicians and physicians in identifying patients with guideline-defined […]
US clinical study proves efficacy of Echo IQ’s heart disease detection technology
Medical technology company Echo IQ (ASX: EIQ) has achieved “clear and positive” results from a clinical effectiveness and validation study at Beth Israel Deaconess Medical Center (BIDMC), located within the Harvard Medical School in the US. The study used Echo’s commercially-ready, artificial intelligence-backed EchoSolv technology to retrospectively analyse 31,141 patient records with the aim of […]
Cashed up Echo IQ tackles the US heart disease market with AI-based diagnostic technology
Heart disease diagnosis innovator Echo IQ (ASX: EIQ) has achieved a “step change in commercial readiness” in progressing its artificial intelligence (AI) based technology for the US market. In its September quarterly report released on Friday, Echo IQ executive chairman Andrew Grover says the company has achieved a number of significant milestones, including a working […]
